content_image/239656.jpg content_image/239650.jpg content_image/239653.jpg
## Medical Devices and Diagnostics Segment Sales Sales by Major Franchise (in billions of dollars) 

<img src='content_image/239656.jpg'>

## Pharmaceutical Segment Sales Sales by Major Product (in billions of dollars) 

<img src='content_image/239650.jpg'>

<img src='content_image/239653.jpg'>

the most significant need. 

In Oncology, Velcade* (bortezomib), for multiple myeloma, grew 16  percent operationally while eclipsing $ 1  billion in sales outside the U.S. for the first time. 

In addition, we continue to pursue line extensions. We submitted applications for several major line extensions, among them REMICADE ®  and SIMPONI ® , which continue to build the strength of our Immunology franchise. 

Over the next three years, we expect to file compounds to address critical medical needs, including Alzheimer’s disease and diabetes, conditions growing in prevalence as the population ages. With five compounds currently in registration and several more planned in the coming years, our portfolio ranks among the leaders in the industry. Our pipeline meets unmet needs and features many true innovations designed to change the treatment paradigm for patients. 

## MEDICAL DEVICES AND DIAGNOSTICS 

The Medical Devices and Diagnostics (MD&D) franchises comprise the world’s largest medical technology business, with sales of $ 24 . 6  billion, an increase of approximately 3  percent operationally. Despite the economic slowdown, which led to a decline in surgical procedures and pricing pressures across the business, we achieved growth in six of our seven franchises, as well as in all regions. 

Our MD&D businesses advanced a very strong pipeline, completed and integrated several acquisitions, and aggressively expanded into emerging markets. The segment maintained or improved market share in the majority of its largest product platforms, despite intense competition. 

For example, the Ethicon franchise grew 8  percent operationally, based on its strong suite of surgical products, as well as recent acquisitions in new markets like aesthetics and ear, nose and throat surgery. The Ethicon Endo-Surgery franchise grew 5  percent operationally. Double-digit growth in its advanced sterilization products and energy products were major contributors. Our Vision Care franchise had operational sales growth of 4  percent based on its core ACUVUE ®  Brand Contact Lens and the continued launch of 1 - DAY ACUVUE ® TruEye ™ Contact Lenses into new markets. The Ortho Clinical Diagnostics franchise grew 4  percent operationally with the continued growth of the VITROS ® 3600  and 5600  analyzers. 

The DePuy franchise increased operational sales by 3  percent based on the strength of its orthopaedic reconstruction, sports medicine and neurological businesses. Diabetes Care increased operational sales by 2  percent with the introduction of a number of new OneTouch $^{®}$ products around the world. Meanwhile, sales in the Cordis franchise continued to decline due to competi- tion in drug-eluting stents. This was partially offset by the strong growth of electrophysiology products in the Biosense Webster business, which grew nearly 20  percent operationally for the year. 

## CONSUMER 

Consumer sales were $ 14 . 6  billion, a decline of approximately 9  percent operationally. Sales were impacted by McNeil recalls, as well as the general economic slowdown and greater consumer sensitivity to spending, reflected in a broad move towards store 

